Swedish Orphan Biovitrum AB SOBI

STO: SOBI | ISIN: SE0000872095   8/07/2025
285,00 SEK (-0,35%)
(-0,35%)   8/07/2025

8 mei 2025 · Bulletin from Sobi's Annual General Meeting (AGM) · Persbericht

29 april 2025 · Sobi publishes Q1 2025 report: Portfolio continues to deliver · Persbericht

1 april 2025 · Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) · Persbericht

31 maart 2025 · Sobi publishes Annual and sustainability report for 2024 · Persbericht

29 augustus 2024 · Sobi has completed issues of class C shares · Persbericht

8 augustus 2024 · Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN · Persbericht

16 juli 2024 · Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance · Persbericht

15 juli 2024 · The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes · Persbericht

2 juli 2024 · Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout · Persbericht

19 juni 2024 · European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A · Persbericht

14 mei 2024 · Bulletin from Sobi's Annual General Meeting (AGM) · Persbericht

26 april 2024 · Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A · Persbericht

25 april 2024 · Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio · Persbericht

4 april 2024 · Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) · Persbericht

2 april 2024 · Sobi publishes Annual and sustainability report for 2023 · Persbericht

8 februari 2024 · Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024 · Persbericht

5 januari 2024 · Sobi's Chairman of the Board resigns due to health reasons · Persbericht

1 november 2023 · Sobi has completed the issuances of series C shares · Persbericht

31 oktober 2023 · Sobi issues series C shares to fulfil its obligations under outstanding incentive programmes · Persbericht

30 oktober 2023 · Sobi publishes Q3 2023 report: Strong revenue and solid performance · Persbericht

Mijn selecties